Emily J. Pomeroy

Emily J. Pomeroy

Auto-generated profile, based on publicly available information

Emily J. Pomeroy

University of Minnesota

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2019 in Nature Communications
Verified
Journal Article
Open access
BWBeau Webber
Beau Webber
CLCara-Lin Lonetree
Cara-Lin Lonetree
MKMitchell G. Kluesner
Mitchell G. Kluesner
MJMatthew J. Johnson
Matthew J. Johnson
EPEmily J. Pomeroy
Emily J. Pomeroy
BMBranden S Moriarity
Branden S Moriarity
The fusion of genome engineering and adoptive cellular therapy holds immense promise for the treatment of genetic disease and cancer. Multiplex genome engineering using targeted nucleases can be used to increase the efficacy and broaden the application of such therapies but carries safety risks associated with unintended genomic alterations and genotoxicity. Here, we apply base editor technology for multiplex gene modification in primary human T cells in support of an allogeneic CAR-T platform and demonstrate that base editor can mediate highly efficient multiplex gene disruption with minimal double-strand break induction. Importantly, multiplex base edited T cells exhibit improved expansion and lack double strand break-induced translocations observed in T cells edited with Cas9 nuclease. Our findings highlight base editor as a powerful platform for genetic modification of therapeutically relevant primary cell types.

1 January 2020 in Molecular Therapy
Verified
Journal Article
Open access
EPEmily J. Pomeroy
Emily J. Pomeroy
JHJohn T. Hunzeker
John T. Hunzeker
MKMitchell G. Kluesner
Mitchell G. Kluesner
WLWalker S. Lahr
Walker S. Lahr
BSBranden A. Smeester
Branden A. Smeester
BMBranden S Moriarity
Branden S Moriarity
Enhancing natural killer (NK) cell cytotoxicity by blocking inhibitory signaling could lead to improved NK-based cancer immunotherapy. Thus, we have developed a highly efficient method for editing the genome of human NK cells using CRISPR/Cas9 to knock out inhibitory signaling molecules. Our method efficiently edits up to 90% of primary peripheral blood NK cells. As a proof-of-principle we demonstrate highly efficient knockout of ADAM17 and PDCD1, genes that have a functional impact on NK cells, and demonstrate that these gene-edited NK cells have significantly improved activity, cytokine production, and cancer cell cytotoxicity. Furthermore, we were able to expand cells to clinically relevant numbers, without loss of activity. We also demonstrate that our CRISPR/Cas9 method can be used for efficient knockin of genes by delivering homologous recombination template DNA using recombinant adeno-associated virus serotype 6 (rAAV6). Our platform represents a feasible method for generating engineered primary NK cells as a universal therapeutic for cancer immunotherapy.

14 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ETErdem D. Tabdanov
Erdem D. Tabdanov
NRNelson Rodriguez
Nelson Rodriguez
ACAlexander Cartagena-Rivera
Alexander Cartagena-Rivera
Vikram PuramVikram Puram
Vikram Puram
MCMackenzie K. Callaway
Mackenzie K. Callaway
PPPaolo Provenzano
Paolo Provenzano
Defining the principles of T cell migration in structurally and mechanically complex tumor microenvironments is critical to understanding escape from antitumor immunity and optimizing T cell-related therapeutic strategies. Here, we engineered nanotextured elastic platforms to study and enhance T cell migration through complex microenvironments and define how the balance between contractility localization-dependent T cell phenotypes influences migration in response to tumor-mimetic structural and mechanical cues. Using these platforms, we characterize a mechanical optimum for migration that can be perturbed by manipulating an axis between microtubule stability and force generation. In 3D environments and live tumors, we demonstrate that microtubule instability, leading to increased Rho pathway-dependent cortical contractility, promotes migration whereas clinically used microtubule-stabilizing chemotherapies profoundly decrease effective migration. We show that rational manipulation of the microtubule-contractility axis, either pharmacologically or through genome engineering, results in engineered T cells that more effectively move through and interrogate 3D matrix and tumor volumes. Thus, engineering cells to better navigate through 3D microenvironments could be part of an effective strategy to enhance efficacy of immune therapeutics.

23 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKMitchell G. Kluesner
Mitchell G. Kluesner
WLWalker S. Lahr
Walker S. Lahr
CLCara-Lin Lonetree
Cara-Lin Lonetree
BSBranden A. Smeester
Branden A. Smeester
XQXiaohong Qiu
Xiaohong Qiu
BMBranden S Moriarity
Branden S Moriarity
CRISPR-Cas9 cytidine and adenosine base editors (CBEs and ABEs) can disrupt genes without introducing double-stranded breaks by inactivating splice sites (BE-splice) or by introducing premature stop (pmSTOP) codons. However, no in-depth comparison of these methods or a modular tool for designing BE-splice sgRNAs exists. To address these needs, we develop SpliceR (http://z.umn.edu/spliceR) to design and rank BE-splice sgRNAs for any Ensembl annotated genome, and compared disruption approaches in T cells using a screen against the TCR-CD3 MHC Class I immune synapse. Among the targeted genes, we find that targeting splice-donors is the most reliable disruption method, followed by targeting splice-acceptors, and introducing pmSTOPs. Further, the CBE BE4 is more effective for disruption than the ABE ABE7.10, however this disparity is eliminated by employing ABE8e. Collectively, we demonstrate a robust method for gene disruption, accompanied by a modular design tool that is of use to basic and translational researchers alike.

26 July 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
HCHui Cong
Hui Cong
XZXinghua Zhao
Xinghua Zhao
BCBrian Castle
Brian Castle
EPEmily J. Pomeroy
Emily J. Pomeroy
BZBo Zhou
Bo Zhou
CZChunlin Zhuang
Chunlin Zhuang

3 October 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
BSBranden A. Smeester
Branden A. Smeester
NSNicholas J. Slipek
Nicholas J. Slipek
EPEmily J. Pomeroy
Emily J. Pomeroy
HBHeather E. Bomberger
Heather E. Bomberger
GSGhaidan A. Shamsan
Ghaidan A. Shamsan
BMBranden S Moriarity
Branden S Moriarity